Article Text

PDF
THU0410 Gout and the risk of incident erectile dysfunction: a body mass index-matched population-based study
  1. N Schlesinger1,
  2. N Lu2,
  3. HK Choi2
  1. 1Medicine, Rutgers/ Robert Wood Johnson Medical School, New Brunswick
  2. 2Medicine, Harvard Medical School, Boston, United States

Abstract

Background Gout is the most common inflammatory arthritis. Erectile dysfunction is common in the general population; however, evidence regarding erectile dysfunction among gout patients is limited.

Objectives Our purpose was to study whether there was an increased risk of erectile dysfunction among gout patients, as compared with the general population.

Methods We conducted a cohort study using The Health Improvement Network, an electronic medical record database in the United Kingdom. Up to five individuals without gout were matched to each case of incident gout by age, enrolment time, and body mass index. Multivariate Hazard Ratios for erectile dysfunction were calculated after adjusting for smoking, alcohol consumption, comorbidities and medication use.

Results We identified 2290 new cases of erectile dysfunction among 38,438 patients with gout (mean age 63.6 years) and 8447 cases among 154,332 individuals in the comparison cohort over a 5-year median follow up (11.9 vs. 10.5 per 1000 person-years, respectively). Univariate (age, entry time and body mass index-matched) and multivariate Hazard Ratios for erectile dysfunction among patients with gout were 1.13 (95% CI, 1.08 to 1.19) and 1.15 (95% CI, 1.09 to 1.21), respectively. In our sensitivity analysis, restricting gout cases to those receiving anti-gout treatment (n=31,227) the magnitude of relative risk was stronger than the primary analysis; (multivariate Hazard Ratios =1.29; 95% CI, 1.22 to 1.37).

Conclusions This population-based study suggests an increased risk of erectile dysfunction among gout patients, supporting a possible role for hyperuricemia and inflammation as independent risk factors for erectile dysfunction.

References

  1. Jackson G, et al. Int J Clin Pract 2002; 56: 663.

  2. Clarson L, et al. Ann Rheum Dis 2015; 74: 4642.

  3. Schlesinger N, et al. J Rheumatol 2015; 42: 1893.

  4. Vlachopoulos C, et al. Eur Urol 2007; 2:1590.

References

Disclosure of Interest N. Schlesinger Grant/research support from: Astra Zeneca, Consultant for: Astra Zeneca, Horizon, Celgene, ProteoThera, Pfizer, N. Lu: None declared, H. Choi Grant/research support from: Astra Zeneca, Consultant for: Takeda, Selecta

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.